A Study of PM8002 in Combination With Chemotherapy in Patients With NEN

Summary

PM8002 is a bispecific antibody targeting PD-L1 and VEGF. This study will evaluate the efficacy and safety of PM8002 in combination with FOLFIRI as second line treatment for neuroendocrine neoplasm (NEC and Ki-67≥55% G3 NET).

Timeline

Start

2023-05-17

Primary completion

2027-01-01

Completion

2028-01-01

Drugs

Indications